"Foreign Chinese medicine" high price re-sales warns the internationalization of Chinese medicine

Recently, the UK's medicines and Health Products Administration (MHRA) released a warning on its website that some traditional Chinese medicines contain large amounts of harmful toxins (including lead, mercury and arsenic) Among them, Niuhuang price antidote tablet of Tongrentang, Baifeng pill of baolingtang and FA Bao of henglongchang are listed Over the years, due to the "green barriers" in foreign countries, the export of traditional Chinese medicine has repeatedly hit a wall As a big country of traditional Chinese medicine, the export volume of traditional Chinese medicine only accounts for 3% - 5% of the world's traditional Chinese medicine market What's more worrying is that foreign pharmaceutical enterprises import herbal extracts from China, and after deep processing in foreign countries, they become "foreign herbal medicine" with high price for resale At present, the export of traditional Chinese medicine products mainly consists of extracts, traditional Chinese medicine and decoction pieces, which are primary processing products and raw materials with low profit margin; on the contrary, the export rate of deep processing and high value-added traditional Chinese medicine with high profit is far behind According to the statistics of China Chamber of Commerce for the import and export of medical and health products, in the first quarter of 2013 alone, the export of plant extracts reached US $330 million, an increase of 11.2% year on year, accounting for 47% of the export of traditional Chinese medicine In recent years, the export of plant extracts in China has increased year by year, reaching US $820 million in 2010, exceeding US $1 billion in 2011 and US $1.16 billion in 2012 After the export of these plant extracts Most of them are sold to China, the world's largest consumer of traditional Chinese medicine According to media reports, jiuxindan, developed by Japanese Jiuxin Pharmaceutical Co., Ltd with traditional Chinese medicine Liushenwan, has achieved sales of hundreds of millions of dollars every year, most of which are from China Germany imports a large number of cheap ginkgo leaves from China every year, and the products produced are resold back to China at a price 10 times higher than the original value According to incomplete statistics, "foreign traditional Chinese medicine" has accounted for one third of the domestic market of Chinese patent medicine Stimulated by the success of Japanese Jiuxin Pharmaceutical Co., Ltd in entering Chinese medicine, more and more multinational companies are seeking opportunities for R & D and investment in traditional Chinese medicine GlaxoSmithKline, which is currently involved in bribery, has previously publicly said that its R & D center in Shanghai will launch research and development of traditional Chinese medicine At the beginning of this year, Lijie, a giant in the UK's FMCG industry, announced its acquisition of Guilin pharmaceutical, a traditional Chinese medicine company Traditional Chinese medicine industry has always been a traditional advantage industry in China It has a long history of thousands of years and is the treasure of the Chinese nation For many years, traditional Chinese medicine (TCM) has occupied half of China's pharmaceutical industry with its advantages of large output, wide distribution and small side effects However, on the other hand, China's lack of attention to the traditional Chinese medicine industry, the technical standard system of the traditional Chinese medicine industry is not perfect, leading to the slow development of the traditional Chinese medicine industry, and the internationalization of traditional Chinese medicine is difficult In recent years, from the opinions of the CPC Central Committee and the State Council on deepening the reform of the medical and health system to the key implementation plan of the reform of the medical and health system to the opinions of the State Council on supporting and promoting the development of the cause of traditional Chinese medicine, China has proposed to give full play to the role of traditional Chinese medicine and to support the development of qualified enterprises, medical institutions, scientific research institutes and universities of traditional Chinese medicine We will expand foreign exchanges and cooperation and promote traditional Chinese medicine to the world Not long ago, the Ministry of Commerce and the State Administration of traditional Chinese medicine said that they would improve policies and regulations related to the trade of traditional Chinese medicine and cultivate international famous brands of traditional Chinese medicine Although the Chinese government is gradually increasing investment in Chinese medicine industry and supporting the construction of Chinese medicine industry, the internationalization of Chinese medicine is still unsatisfactory For example, among the 55 listed Chinese medicine enterprises of a share, only 17 Chinese medicine companies have cross-border trade clearly disclosed in the performance report, and most of them are less than 10% of their annual revenue, and their business is still limited in the domestic market Due to the complexity of composition and processing technology, it is difficult to quantify the efficacy and quality control of traditional Chinese medicine, so it is difficult to be recognized by the international market With the increasingly standardized monitoring of adverse drug reactions and the continuous occurrence of adverse drug reactions of traditional Chinese medicine such as Longdan Xiegan pill and Houttuynia price injection, the traditional Chinese medicine industry has been unable to avoid the lack of modern pathology and toxicology of traditional Chinese medicine At present, European and American countries have very strict standards in the review of Chinese herbal medicine, both in the standard setting and drug quality testing, while the domestic standards are relatively loose As a result, many well-selling traditional Chinese medicines in China are difficult to export, so they can only be used as health care products and food in the European and American markets Therefore, the internationalization of traditional Chinese medicine first needs to establish a complete quality standard of traditional Chinese medicine It is advisable to draw lessons from "foreign traditional Chinese medicine", establish a complete and effective standard system, and seize the commanding point of the world standard competition of traditional Chinese medicine We should improve our own standards from the sources of medicinal materials, extraction and separation, R & D and production, quality control and other aspects; we should take necessary measures to determine the content of heavy metals, pesticide residues and effective ingredients of traditional Chinese medicine, which are of international concern, and formulate feasibility standards Secondly, the internationalization of traditional Chinese medicine should take technology as a sharp tool, improve the technical level of Chinese medicine enterprises as soon as possible, and improve the scientific and technological content of traditional Chinese medicine According to statistics, more than 60% of Chinese medicine products rejected by importing countries fall under the "green barrier" Due to the microbial pollution, heavy metal, pesticide residues, chemical pollution and other problems of traditional Chinese medicine products, the export is often blocked Enterprises should actively implement the high-tech strategy, improve the quality to meet the international standards, and speed up the development of the international market of traditional Chinese medicine.